GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Enzychem Lifesciences Corp (XKRX:183490) » Definitions » Effective Interest Rate on Debt %

Enzychem Lifesciences (XKRX:183490) Effective Interest Rate on Debt % : 4.99% (As of Mar. 2025)


View and export this data going back to 2013. Start your Free Trial

What is Enzychem Lifesciences Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Enzychem Lifesciences's annualized positive value of Interest Expense for the quarter that ended in Mar. 2025 was ₩232 Mil. Enzychem Lifesciences's average total debt for the quarter that ended in Mar. 2025 was ₩4,657 Mil. Therefore, Enzychem Lifesciences's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2025 was 4.99%.


Enzychem Lifesciences Effective Interest Rate on Debt % Historical Data

The historical data trend for Enzychem Lifesciences's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enzychem Lifesciences Effective Interest Rate on Debt % Chart

Enzychem Lifesciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Effective Interest Rate on Debt %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.19 20.01 22.35 2.86 4.53

Enzychem Lifesciences Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.72 5.14 5.21 4.88 4.99

Competitive Comparison of Enzychem Lifesciences's Effective Interest Rate on Debt %

For the Drug Manufacturers - Specialty & Generic subindustry, Enzychem Lifesciences's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enzychem Lifesciences's Effective Interest Rate on Debt % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Enzychem Lifesciences's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Enzychem Lifesciences's Effective Interest Rate on Debt % falls into.


;
;

Enzychem Lifesciences Effective Interest Rate on Debt % Calculation

Enzychem Lifesciences's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2024 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2023 )+Total Debt  (A: Dec. 2024 ))/ count )
=-1  *  -238.697/( (5656.959+4879.944)/ 2 )
=-1  *  -238.697/5268.4515
=4.53 %

where

Total Debt  (A: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=1609.453 + 4047.506
=5656.959

Total Debt  (A: Dec. 2024 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=345.002 + 4534.942
=4879.944

Enzychem Lifesciences's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2025 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Dec. 2024 )+Total Debt  (Q: Mar. 2025 ))/ count )
=-1  *  -232.456/( (4879.944+4433.671)/ 2 )
=-1  *  -232.456/4656.8075
=4.99 %

where

Total Debt  (Q: Dec. 2024 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=345.002 + 4534.942
=4879.944

Total Debt  (Q: Mar. 2025 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=819.4 + 3614.271
=4433.671

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Mar. 2025) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.


Enzychem Lifesciences  (XKRX:183490) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.


Enzychem Lifesciences Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Enzychem Lifesciences's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.


Enzychem Lifesciences Business Description

Traded in Other Exchanges
N/A
Address
27 Gangnamdae-ro Seocho-gu, 10th Floor, aT Center, Seoul, KOR, 135-280
Enzychem Lifesciences Corp develops and produces APIs and functional health foods. It manufactures veterinary medicine tablets, capsules, syrups, injections, ointments, solutions for the diagnosis and prevention of various diseases. The company is also developing drugs to treat chemotherapy-induced neutropenia, chemo-radiation therapy-induced oral mucositis, asthma, psoriasis, rheumatoid arthritis, and others.

Enzychem Lifesciences Headlines

No Headlines